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ABSTRACT
T-cell intracellular antigen-1 (TIA1) is an RNA-binding protein involved in 
many regulatory aspects of mRNA metabolism. Here, we report previously unknown 
tumor-promoting activity of TIA1, which seems to be associated with its isoform-
specific molecular distribution and regulation of a set of cancer-related transcripts, in 
esophageal squamous cell carcinoma (ESCC). Immunohistochemical overexpression 
of TIA1 ectopically localized in the cytoplasm of tumor cells was an independent 
prognosticator for worse overall survival in a cohort of 143 ESCC patients. Knockdown 
of TIA1 inhibited proliferation of ESCC cells. By exogenously introducing each of two 
major isoforms, TIA1a and TIA1b, only TIA1a, which was localized to both the nucleus 
and cytoplasm, promoted anchorage-dependent and anchorage-independent ESCC 
cell proliferation. Ribonucleoprotein immunoprecipitation, followed by microarray 
analysis or massive-parallel sequencing, identified a set of TIA1-binding mRNAs, 
including SKP2 and CCNA2. TIA1 increased SKP2 and CCNA2 protein levels through 
the suppression of mRNA decay and translational induction, respectively. Our findings 
uncover a novel oncogenic function of TIA1 in esophageal tumorigenesis, and implicate 
its use as a marker for prognostic evaluation and as a therapeutic target in ESCC.
INTRODUCTION
Esophageal cancer is the eighth most common 
cancer worldwide, and the sixth most common cause of 
death from cancer [1]. Despite the advances in multimodal 
therapies, the outcome of this disease remains poor [2]. 
In Asian countries, including Japan, esophageal squamous 
cell carcinoma (ESCC) lacking accessible genomic 
characteristics accounts for > 90% of esophageal cancers 
[3]. The identification of deregulated molecules that lead 
to unrestrained cell growth and/or cell death evasion 
during carcinogenesis is needed for the establishment of 
novel prognostic markers and therapeutic targets to guide 
individualized treatment of ESCC.
RNA-binding proteins (RBPs) coordinate the 
lives of mRNAs by contributing to various post-
transcriptional modification processes under both 
physiological and pathological conditions [4, 5]. 
Given the central role of RBPs in the regulation of 
gene expression, malfunction of RBP or mutations in 
the RNA elements they recognize can lead to cancer 
development and progression. Indeed, several RBPs 
have been reported to be involved in carcinogenesis by 
increasing or decreasing expression of various genes [6–8]. 
Oncotarget17112www.impactjournals.com/oncotarget
In addition, a global comparison of the transcriptional 
profiles in the Cancer Genome Atlas Pan-Cancer Dataset 
revealed that a significant change in RBP expression occurs 
and contributes to the dysregulated transcription of a set 
of oncogenes and tumor-suppressor genes across most 
cancer types [9]. However, the significance of RBPs in 
carcinogenesis remains primarily unknown.
The T-cell intracellular antigen-1 gene (TIA1) encodes 
TIA1 protein, a cytotoxic granule-associated RBP that 
possesses nucleolytic activity against cytotoxic lymphocyte 
(CTL) target cells [10]. TIA1 also acts as a stress-induced 
inhibitor of translation by localizing to stress granules 
(SGs) with polyA RNA and contributes to the induction of 
apoptosis in CTL targets [11–13]. The two alternative splice 
transcripts, TIA1 variant 1 (TIA1-v1, NM_022173.2) and 
variant 2 (TIA1-v2, NM_022037.2), which lack and include 
exon 5, respectively, encode two different isoforms, TIA1b 
(or TIA1 isoform 2, NP_071505.2) and TIA1a (or TIA1 
isoform 1, NP_071320.2), respectively [14]. Although 
several reports refer to the relationship between TIA1 and 
epithelial carcinogenesis [14], the significance of TIA1 and/
or its isoforms in ESCC remains unclear. 
In this study, we first report the importance of 
TIA1, particularly the TIA1a isoform, as a molecule 
exerting oncogenic activity by ectopically localizing to the 
cytoplasm and increasing/decreasing the expression of a 
set of cancer-related genes, including SKP2 and CCNA2, 
in the malignant progression of ESCC. 
RESULTS
TIA1 protein expression and its association with 
the clinicopathological characteristics in ESCC
To determine the clinical significance of TIA1 
in esophageal carcinogenesis, immunohistochemical 
staining (IHC) was performed in surgically resected tissues 
(Figure 1A). TIA1 immunoreactivity was observed 
primarily in the nucleus of normal esophageal epithelia 
and in dysplasic lesions, which displayed higher TIA1 
immunoreactivity than the normal mucosa. In carcinoma 
in situ and advanced cancers, TIA1 staining was observed 
in both the cytoplasm and the nucleus, and cytoplasmic 
TIA1 immunoreactivity was higher in advanced cancers 
than in carcinoma in situ. Notably, higher immunoreactivity 
toward Ki-67, a cell proliferation marker, was observed 
preferentially in tumor cells with higher cytoplasmic TIA1 
immunoreactivity (Figure 1B), suggesting that cytoplasmic 
TIA1 promotes the proliferation of ESCC cells [15, 16]. 
A similar pattern of TIA1 immunoreactivity was observed in 
squamous cell carcinomas of other tissues (Supplementary 
Figure S1A). 
We then examined the clinicopathological significance 
of TIA1 expression in primary ESCC tumors based on 
the IHC staining pattern (Supplementary Figure S1B). 
Among 143 cases, positive cytoplasmic and nuclear TIA1 
immunoreactivities were observed in 79 (55.2%) and 69 
(48.3%) patients, respectively, based on their intensity 
scores (Table 1). Because positive cytoplasmic and nuclear 
TIA1 immunoreactivities were detected at the same 
levels between patients with and without neoadjuvant 
chemotherapy with 5-fluorouracil plus cisplatin (FP, 
Supplementary Tables S1 and S2), we combined all patients 
for further analyses. No significant association was observed 
between any clinicopathological factors and nuclear or 
cytoplasmic TIA1 immunoreactivity (Table 1). Kaplan–
Meier survival estimates showed that positive cytoplasmic 
TIA1 immunoreactivity was significantly associated with 
worse overall survival in all 143 cases (P = 0.0003), but 
nuclear TIA1 immunoreactivity was not (Figure 1C). 
No synergistic effect between positive cytoplasmic and 
nuclear TIA1 immunoreactivities on overall survival 
was observed even after dividing ESCC cases into four 
groups according to both cytoplasmic and nuclear TIA1 
staining patterns (Supplementary Figure S1C). In the Cox 
proportional hazards regression model, cytoplasmic TIA1 
immunoreactivity, lymphatic invasion, venous invasion, 
pT and pN categories, and preoperative therapy procedures 
were statistically significant prognosticators for overall 
survival by univariate analyses (Table 2). Multivariate 
analyses showed that cytoplasmic TIA1 immunoreactivity 
and pT and pN categories were independent predictive 
factors regardless of the models used (Table 2), suggesting 
that overexpressed TIA1 is involved in the development and 
progression of ESCC through cytoplasmic localization. 
Expression of TIA1 in ESCC cell lines
TIA1 mRNA overexpression, compared with the 
esophagus, was also detected in 30 of 45 ESCC cell lines 
by quantitative real-time PCR (qPCR, Supplementary 
Figure S2A). Similarly, TIA1 protein overexpression was 
observed in most of cancer cells compared with normal 
mucosa (Supplementary Figure S2B). The human TIA1 gene 
generates two major variants (v1 and v2) through alternative 
splicing of exon 5, encoding the shorter TIA1b and longer 
TIA1a isoforms, respectively (Figure 2A). TIA1 contains 
three domains with RNA recognition motifs (RRMs), and 
the 11 amino acids encoded by exon 5 are located between 
RRM1 and RRM2. Most ESCC cells constitutively express 
TIA1-v2 mRNA and a small amount of TIA1-v1 mRNA 
(Supplementary Figure S3A), resulting in the predominant 
expression of TIA1a protein compared with TIA1b protein 
(Supplementary Figure S2B). Similarly, both non-tumor and 
tumor tissues of primary ESCC predominantly expressed 
TIA1-v2 mRNA, and the TIA1 mRNA expression levels in 
tumors were higher than in those in paired non-tumor tissues 
in 3/6 (50%) of ESCC cases whose RNA was available 
(Supplementary Figure S3B). Western blot analysis using 
subcellular components obtained by cell fractionation 
showed that endogenous TIA1b was detected primarily in 
the nuclear lysate, whereas endogenous TIA1a was detected 
in both nuclear and cytoplasmic lysates, although most 
TIA1a was located in the nucleus (Figure 2B). Exogenously 
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expressed TIA1b protein in KYSE2270 cells with lower 
endogenous TIA1 expression localized predominantly to the 
nucleus, while a larger fraction of the exogenously expressed 
TIA1a protein localized to the cytoplasm compared with 
TIA1b protein, as demonstrated by western blot analysis 
(Figure 2C) and by fluorescent immunocytochemical 
staining (FIC, Figure 2D). 
Involvement of TIA1 in ESCC cell proliferation
To gain insight into the potential function of 
TIA1 whose overexpression could be associated with 
esophageal carcinogenesis, we first tested the effects of 
small interfering RNA (siRNA) targeting TIA1 on cell 
proliferation. By silencing endogenous TIA1 using three 
different siRNAs, cell proliferation was significantly 
suppressed in KYSE140, KYSE180 and TE4 cells. In 
TE8 cells, which express lower levels of TIA1, treatment 
with TIA1-specific siRNAs led to minimal suppression 
(Figure 3A–3C). FIC demonstrated that Ki-67 expression 
correlated with TIA1 expression; cells that retained TIA1 
expression tested positive for Ki-67 expression, whereas 
cells in which TIA1 was effectively knocked down tested 
negative for Ki-67 expression (Supplementary Figure 
S4A). Using fluorescence-activated cell sorting (FACS) 
analysis to examine the mode of action of TIA1 in the 
cell cycle, an accumulation of cells in G0–G1 phase, with 
an accompanying increase in sub-G1 phase cells and a 
decrease in S and G2–M phase cells, was observed in TIA1 
siRNA-treated cells compared with control siRNA-treated 
cells (Figure 3D). Knockdown of endogenous TIA1 
significantly increased p21WAF1/Cip1 and p27Kip1 protein 
levels, with extensive cleavage of caspase-3, caspase-7 
and poly [ADP ribose] polymerase (PARP), which are 
markers of apoptosis (Figure 3E). These results suggest 
that TIA1 silencing in ESCC cells contributes to cell 
cycle arrest at the G1-S checkpoint and the induction of 
apoptosis. 
We next introduced a TIA1[v1]- or TIA1[v2]-
expressing retrovirus into KYSE190 and KYSE2270 cells 
Figure 1: TIA1 protein overexpression and localization and its association with overall survival in primary ESCC 
tumors. (A) Representative results of the immunohistochemical detection of TIA1 protein in normal mucosa, dysplasia, carcinoma 
in situ and advanced squamous cell carcinoma of the esophagus. Scale bars: 40 μm. (B) Representative results of the immunohistochemical 
detection of TIA1 and Ki-67 in serial sections of primary ESCC tissues. Scale bars: 40 μm. (C) Kaplan–Meier curves for overall survival 
rates of 143 ESCC patients according to the cytoplasmic (left) and nuclear (right) expression levels of TIA1 protein. The log-rank test was 
used for statistical analysis. Differences resulting in values of P < 0.05 are considered statistically significant. 
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Table 1: Association between clinicopathological characteristics and TIA1 expression
Clinicopatho logical 
factors n
TIA1 
immunoreactivity 
(Cytoplasm) P valuea
TIA1 
immunoreactivity 
(Nucleus) P 
valuea
TIA1 
immunoreactivity 
(Whole) P 
valuea
Positive 
(%)
Negative 
(%)
Positive 
(%)
Negative 
(%)
Positive 
(%)
Negative 
(%)
Total 143 79 (55.2) 64 (44.8) 69 (48.3) 74 (51.7) 67 (46.9) 76 (53.1)
Gender
    Male 117 69 (59.0) 48 (41.0)
0.0574 
53 (45.3) 64 (54.7)
0.1329
57 (48.7) 60 (51.3)
0.7523 
    Female 26 10 (38.5) 16 (61.5) 16 (61.5) 10 (38.5) 10 (38.5) 16 (61.5)
Age
     Mean ± SD 
(yr)
63.2 ± 
7.3 62.8 ± 7.5
63.7 ± 
6.9 0.4047 
62.7 ± 
6.5
63.7 ± 
7.9 0.5228
62.7 ± 
6.59 63.6 ± 7.84 0.4924 
Locationb 
    Upper 27 12 (44.4) 15 (55.6)
0.1526 
14 (51.9) 13 (48.1)
0.5404
12 (44.4) 15 (55.6)
0.9272     Middle 69 36 (52.2) 33 (47.8) 30 (43.5) 39 (56.5) 32 (46.4) 37 (53.6)
    Lower 47 31 (66.0) 16 (34.0) 25 (53.2) 22 (46.8) 23 (48.9) 24 (51.1)
Histopathological gradingc
     Well and 
moderately 
differentiated
96 55 (57.3) 41 (42.7)
0.4822 
46 (47.9) 51 (53.1)
0.6378
44 (45.8) 52 (54.2)
0.7270 
    Poorly 47 24 (51.1) 23 (48.9) 24 (51.1) 23 (48.9) 23 (48.9) 24 (51.1)
Size
     Mean ± SD 
(mm)
45.2 ± 
26.9
46.5 ± 
26.2
43.7 ± 
27.7 0.4189
46.2 ± 
27.2
44.4 ± 
26.7 0.6248
47.2 ± 
27.7 43.5 ± 26.1 0.4675 
Lymphatic invasion (ly)
    Negative 68 44 (64.7) 31 (45.6)
0.3873 
33 (48.5) 35 (51.5)
0.9496
32 (47.1) 36 (52.9)
0.9626
    Positive 75 35 (51.5) 33 (48.5) 36 (52.9) 39 (57.4) 35 (46.7) 40 (53.3)
Venous invasion (v)
    Negative 88 32 (36.4) 23  (26.1) 43 (48.9) 45 (51.1) 0.8530
42 (47.7) 46 (52.3)
0.7910
    Positive 55 47 (53.4) 41 (46.6) 0.5762 26 (29.5) 29 (33.0) 25 (45.5) 30 (54.5)
Depth of tumor invasion (pT)
    pT1 55 26 (47.3) 29 (52.7)
0.1298
25 (45.5) 30 (54.5)
0.5965
25 (45.5) 30 (54.5)
0.7910
    pT2-4 88 53 (60.2) 35 (39.8) 44 (50.0) 44 (50.0) 42 (47.7) 46 (52.3)
N stage (pN)
    pN0 51 26 (51.0) 25 (49.0)
0.4455 
23 (45.1) 28 (54.9)
0.5739 
22 (43.1) 29 (56.9)
0.5069 
    pN1-3 92 53 (57.6) 39 (42.4) 46 (50.0) 46 (50.0) 45 (48.9) 47 (51.1)
pStage
    pI 36 21 (58.3) 15 (41.7)
0.6660 
15 (41.7) 21 (58.3)
0.3596 
17 (47.2) 19 (52.8)
0.9591 
    pII-VI 107 58 (54.2) 49 (45.8) 54 (50.5) 53 (49.5) 50 (46.7) 57 (53.3)
Neoadjuvant therapyd
    Absent 78 47 (60.3) 31 (39.7)
0.1866
37 (47.4) 41 (52.6)
0.8306
40 (51.3) 38 (48.7)
0.2444
    Present 65 32 (49.2) 33 (50.8) 32 (49.2) 33 (50.8) 27 (41.5) 38 (58.5)
Statistically significant value are in boldface type.
aP value are from χ2 or Fisher’s exact test and were statistically significant at < 0.05.
bUpper, cervical + upper thoracic esophagus; Middle, mid-thoracic esophagus; Lower, lower thoracic + abdominal esophagus.
cWell, well differentiated SCC; Moderate, moderate differentiated SCC; Poorly, poorly differentiated SCC.
dNeoadjuvant therapy, preoperative treatment with FP [5-fluorouracil (800 mg/body/day) plus cisplatin (80 mg/body/day)].
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Table 2: Cox proportional hazard regression analysis for overall survival
Univariate
Multivariatea
Model 1 Model 2 Model 3
Hazard 
ratio
95% confidence 
interval P value P value P value P value
Gender 
    Male versus Female 1.04 0.5502−2.1854 0.9058 0.7848 – –
Age
    > 65 yr versus < 65 yr 1.07 0.6335−1.7892 0.8029 0.6317 – –
Histopathological grading
Poorly versus Well-moderately 
differentiated 1.16 0.6758−1.9660 0.5733 0.6501 – –
Size 
    > 40 versus < 40 1.64 0.9798−2.7823 0.0597 0.4626 – –
Lymphatic invasion
    Positive versus Negative 2.06 1.2200−3.5765 0.0066 0.1544 0.1912 –
Venous invasion 
    Positive versus Negative 1.69 1.0044−2.8334 0.0481 0.8674 0.9900 –
Depth of tumor invasion (pT)
    pT2-3 versus pT1 3.91 2.0659−8.2066 < 0.0001 0.0192 0.0195 0.0044 
N stage (pN)
    pN1-3 versus pN0 4.70 2.3546−10.7289 < 0.0001 0.0013 0.0020 0.0007 
Neoadjuvant chemotherapy
    Positive versus Negative 1.84 1.0893−3.1287 0.0226 0.4305 0.2573 –
TIA1 immunoreactivity in the 
cytoplasm
    Positive versus Negative 2.84 1.1619−5.2878 0.0002 0.0059 0.0033 0.0024 
TIA1 immunoreactivity in the 
nucleus
    Positive versus Negative 1.20 0.7149−2.0146 0.4913 - – –
Note: Statistically significant value are in boldface type.
aModel 1, all factors excluding TIA1 immunoreactivity in the nucleus model were included;  
 Model 2, factors whose p-value < 0.05 in the univariate analysis were included;
 Model 3, a step-wise procedure was used.
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expressing relatively lower levels of endogenous TIA1 
to determine the effects of exogenously expressed TIA1 
isoforms. Notably, PARP cleavage was pronounced only in 
TIA1b-overexpressing cells (Figure 4A). Colony formation 
assays revealed that TIA1a-expressing cells formed 
more colonies than control and TIA1b-expressing cells 
(Figure 4B). Anchorage-independent in vitro 3D cell culture 
showed that exogenously expressed TIA1a accelerated 
spheroid formation, while exogenously expressed TIA1b 
inhibited spheroid formation (Figure 4C). Furthermore, 
higher Ki-67 expression was observed in cells exogenously 
expressing TIA1a, compared with cells lacking exogenous 
TIA1a expression (Supplementary Figure S4B). These results 
indicate the distinct functions of TIA1a and TIA1b in ESCC 
cells: TIA1a promotes anchorage-dependent and anchorage-
independent cell proliferation, while TIA1b does not. These 
distinct functions of two isoforms were partially supported 
by knockdown experiments using isoform-specific siRNAs 
even though these siRNAs showed limited specificity and 
efficiency (Supplementary Figure S5A). In comparison with 
depletion of TIA1b, anchorage-dependent cell proliferation 
was more effectively suppressed by depletion of TIA1a with 
an increased p21WAF1/Cip1 protein level and extensive cleavage 
of PARP (Supplementary Figure S5A, S5B).
To determine the chronic effects of each TIA1 
isoform on ESCC cell proliferation in vitro, we established 
stable transfectants expressing FLAG-tagged TIA1a or 
TIA1b protein using KYSE190 and KYSE2270 cells. 
Stable expression of TIA1a increased cell proliferation 
compared with control cells (Figure 4D). Consistent with 
the observations in the transient transfection experiments, 
stable expression of TIA1b facilitated cell death in most 
cell lines during isolation and subculture after transfection 
of the construct. FACS analysis indicated an accumulation 
of cells in S and G2–M phase and a decrease in G0–G1 
phase cells in TIA1a-expressing cells compared with 
control cells (Figure 4E). Taken together, these results 
suggest that TIA1a contributes to the anchorage-
dependent and anchorage-independent growth of ESCC 
cells in vitro.
Identification of putative target mRNAs for 
cytoplasmic TIA1 
We further investigated the molecular mechanisms 
of cytoplasmic TIA1-promoted ESCC cell growth. 
Cytoplasmic TIA1 was shown to bind to transcripts through 
their 5′ and/or 3′ untranslated regions (UTRs) and to alter 
their localization, stability and/or translation [11, 16–21]. 
Therefore, we screened putative TIA1-binding mRNAs 
using ribonucleoprotein immunoprecipitation (RIP), 
which was conducted using lysates prepared from the 
cytoplasm and anti-TIA1 antibody, followed by microarray 
analysis (RIP-chip) or massive-parallel sequencing (RIP-
seq) in KYSE180 cells. We identified 2,679 mRNAs 
whose enrichment in TIA1 immunoprecipitates differed 
by > 2.5-fold compared with that of GAPDH mRNA 
in both RIP-chip and RIP-seq (Supplementary Table 
S3). Gene Ontology (GO) analysis using these 2,679 
mRNAs ranked ‘mitotic cell cycle’ (P = 6.04E–14) and 
‘cell cycle’ (P = 4.23E–11) as the two top biological 
processes (Supplementary Table S4). Pathway analysis 
using the Kyoto Encyclopedia of Genes and Genomes 
(KEGG) database with 2,679 mRNAs also ranked 
‘cell cycle’ (P = 1.14E–14) as the most significant 
functional pathway (Table 3). Of the top 207 transcripts 
annotated as ‘cell cycle’ by GO analysis (Supplementary 
Table S5), we focused on nine well-known cell cycle 
regulators (CCNA2, CCND1, CDK6, CHK1, CHK2, 
MAPK1, MAP2K1, SKP2, and TFDP1) for further 
analyses, due to their known functions in cancers. 
The binding of these genes with TIA1 protein was 
successfully validated by RIP followed by qPCR; their 
affinities were similar to the known TIA1-binding 
transcript FAS mRNA (Figure 5A and Supplementary 
Figure S6A) [22]. The binding of each TIA1 isoform to 
these candidate targets was assessed using exogenously 
expressed each FLAG-tagged TIA1 isoform in HEK293 
cells (Supplementary Figure S7A). TIA1a showed more 
potent binding to each mRNA than TIA1b, although 
both isoforms bound to all of the mRNAs we analyzed 
(Supplementary Figure S7B).
To investigate the consequences of the binding 
between TIA1 and these nine genes in ESCC cells, the 
effects of TIA1 knockdown on the levels of these mRNAs 
and FAS mRNA were examined. TIA1 knockdown did not 
significantly influence the levels of most of these mRNAs, 
although SKP2 mRNA levels decreased moderately (Figure 
5B and Supplementary Figure S6B). In those nine genes, 
the effects of TIA1 knockdown on the levels of the proteins 
encoded by the SKP2, CCNA2, CHK1 and CHK2 mRNAs 
were assessed. Compared with control siRNA-treated cells, 
TIA1 siRNA-treated KYSE140, KYSE180 and TE4 cells 
showed lower levels of SKP2 and CCNA2 proteins and 
higher levels of CHK1 and CHK2 proteins (Figure 5C). 
Since SKP2 and CCNA2 are known to be implicated in 
the pathogenesis of various cancers as oncogenes (23–27), 
the effects of each TIA1 protein isoform on the SKP2 
and CCNA2 protein levels were investigated using cells 
transiently expressing each isoform via retroviral infection. 
Cells exogenously expressing TIA1a showed higher levels 
of SKP2 and CCNA2 protein compared with control cells. 
In contrast, cells exogenously expressing TIA1b did not 
show any increase in SKP2 protein, although KYSE190 
cells expressing TIA1b showed higher levels of CCNA2 
protein (Figure 5D). The increased SKP2 mRNA level was 
observed in cells exogenously expressing TIA1a but not in 
cells exogenously expressing TIA1b, whereas the CCNA2 
mRNA level was not changed in either cells exogenously 
expressing TIA1a or TIA1b (Supplementary Figure S6C). 
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Binding and functional association between 
TIA1 and cancer-associated mRNAs 
The binding between TIA1 protein and SKP2 and 
CCNA2 mRNAs was further analyzed by pulldown assays 
using biotinylated partial SKP2 and CCNA2 mRNA 
fragments spanning the 5′ UTR, open reading frame (ORF), 
or 3′ UTR in cytoplasmic lysates prepared from KYSE180 
cells (Figure 6A). SKP2 mRNA bound to TIA1 through its 
ORF and 3′ UTR, while CCNA2 mRNA bound to TIA1 
through its 5′ UTR and ORF. Previous studies showed that 
the binding of RBPs with the 5′ UTRs of mRNAs alters their 
Figure 2: Subcellular distribution of the TIA1 isoforms. (A) Schematic structures of the TIA1a and TIA1b protein isoforms with 
and without 11 amino acids, translated from the TIA1-v2 and TIA1-v1 transcripts, respectively. Both isoforms include three RNA recognition 
motifs (RRM) and a carboxyl-terminal glutamine-rich domain (Q-rich domain). Numbers indicate amino acid residues corresponding to 
each TIA1 isoform. (B) Subcellular distribution of endogenous TIA1 in ESCC cells. Cytoplasmic and nuclear fractions were prepared from 
KYSE140, KYSE180, TE4 and TE8 cells. Amounts of TIA1, β-tubulin (cytoplasmic marker) and hnRNPC1/C2 (nuclear marker) were 
measured by western blot. The intensities of specific bands corresponding to the TIA1 isoforms were measured with a densitometer and are 
presented as ratios in the inset. (C) The subcellular distribution of exogenously expressed TIA1 isoforms. Cytoplasmic and nuclear fractions 
were prepared from KYSE2270 cells stably transfected with mock-, TIA1a- or TIA1b-expressing constructs. Amounts of exogenous (exo) 
and endogenous (end) TIA1 isoforms (arrowheads), β-tubulin (cytoplasmic marker) and hnRNPC1/C2 (nuclear marker) were measured by 
western blot analysis. (D) Representative images of exogenously expressed FLAG-tagged TIA1 isoforms in KYSE2270 cells detected by 
FIC using anti-FLAG antibody (green). Nuclei were counterstained with DAPI (blue). Scale bars: 20 μm.
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Figure 3: Effects of TIA1 knockdown on cell proliferation. (A) KYSE140, KYSE180, TE4 or TE8 cells were transfected with 
each 10 nM TIA1-specific or control siRNA for 48 h, and the TIA1 mRNA expression levels were evaluated by qPCR using GAPDH 
mRNA as an endogenous control. The values are expressed as fold changes (mean ± SD, n = 3) compared with the respective values in 
control siRNA-transfected cells. *significantly different from the control value by Student’s t test (P < 0.05). (B) Effectiveness of siRNA 
transfection. KYSE140, KYSE180, TE4 or TE8 cells were treated as described in (A), and the expression levels of TIA1 protein were 
evaluated by western blot analysis using GAPDH as a loading control. (C) KYSE140, KYSE180, TE4 or TE8 cells were transfected with 
each 10 nM TIA1-specific or control siRNA for 24 h, and cellular proliferation was measured using a WST assay at the indicated times. The 
values are expressed as fold changes (mean ± SD, n = 4) compared with the respective values in control cells (0 h). *significantly different 
from the control value by Student’s t test (P < 0.05). (D) Representative results of cell cycle analysis. After KYSE140 or TE4 cells were 
treated with 10 nM TIA1-specific or control siRNA for 48 h, then the cells were stained with PI and subjected to FACS analysis. Raw data 
were quantified for cell cycle analysis by FACSVerse software. (E) KYSE140, KYSE180, TE4 and TE8 cells were transfected with 10 nM 
TIA1-specific or control (-) siRNA for 48 h. Levels of caspase-3, caspase-7, PARP, p21WAF1/Cip1, p27Kip1 and TIA1 proteins were measured 
by western blot analysis using GAPDH as a loading control.
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Figure 4: TIA1a promotes cell proliferation in ESCC cells. (A) KYSE190 and KYSE2270 cells were transiently infected with a 
mock, TIA1a-, or 1b-expressing retroviruses, and the levels of PARP and exogenous TIA1 (exo) isoforms were measured by western blot 
analysis using GAPDH as a loading control. (B) KYSE190 cells transiently infected with either a mock-, pTIA1[v1]-FLAG- or pTIA1[v2]-
FLAG-expressing retrovirus (1,000 cells/well) were plated in six-well plates and treated with 0.5 mg/mL G418 for two weeks. The colonies 
in each well were stained with crystal violet, and the colony areas were calculated using ImageJ software. *significantly different from the 
control value by Student’s t test (P < 0.05). (C) For spheroid formation assay, KYSE190 cells transiently transfected with mock or each 
TIA1 isoform were seeded in ultra-low attachment 96-well round bottom plates and incubated at 37°C for the indicated times (d, days). 
The areas of spheroids were determined as described in the Materials and Methods section (mean ± SD, n = 8). *significantly different 
from the control value by Student’s t test (P < 0.05). (D) The number of viable cells of each stable transfectant was assessed using a WST 
assay for the indicated times. The values are expressed as fold changes (mean ± SD, n = 4) compared with the respective control values 
(0 h). *, significantly different from the control value by Student’s t test (P < 0.05). (E) Representative results of FACS analysis using stable 
transfectants. The raw data were quantified for cell cycle analysis using FACSVerse software. 
Oncotarget17120www.impactjournals.com/oncotarget
translation, while their binding with the 3′ UTRs of mRNAs 
changes the stability of these transcripts [16, 17]. In an 
mRNA decay assay using KYSE180 cells, TIA1 knockdown 
decreased the stability of SKP2 mRNA but did not alter that 
of CCNA2 mRNA (Figure 6B). Stable overexpression of 
TIA1a increased the stability of SKP2 mRNA in KYSE190 
and KYSE2270 cells (Supplementary Figure S8A). In an 
mRNA decay assay using KYSE140 and KYSE180 cells 
transfected with reporter constructs containing the coding 
sequence (CDS) of the firefly luciferase gene (Luc2) with 
the 3′ UTR of SKP2 or Luc2 alone, TIA1 knockdown 
decreased the Luc2 mRNA expression level (Figure 6C 
and Supplementary Figure S8B). In an mRNA decay 
assay using cells transfected with the expression construct 
containing FLAG-tagged SKP2 CDS, on the other hand, 
TIA1 knockdown did not change the FLAG-tagged SKP2 
mRNA expression level (Supplementary Figure S8C). 
Those results suggest that TIA1 increases the SKP2 mRNA 
stability through binding to its 3′ UTR. In ESCC cells, 
TIA1 depletion did not affect the change of exogenously 
expressed FLAG-tagged CCNA2 protein level after 
addition of cycloheximide (Supplementary Figure S9A). In 
the polysome profiling assay using KYSE180 cells, TIA1 
depletion caused a shift in CCNA2 mRNA from heavy to 
light polysomal fractions (Figure 6D and Supplementary 
Figure S9B). Those results suggest that TIA1 reduction 
induced decreased translation initiation of CCNA2 mRNA 
without the stability of CCNA2 protein, although binding 
site of TIA1 to CCNA2 mRNA necessary for this translation 
promoting effect remains undetermined.
The correlation between the TIA1 and SKP2/CCNA2 
protein levels was tested in ESCC tumors. In 52 tumors for 
which serial sections were available, IHC revealed that the 
expression levels of SKP2 and CCNA2 proteins in tumor 
cells correlated positively with the cytoplasmic TIA1 
expression level (Figure 6E) and tended to be associated 
with worse overall survival (Supplementary Figure S10A 
and S10B), although CCNA2 immunoreactivity did not 
reach a statistically significant level. In addition silencing 
of either SKP2 or CCNA2 in stable TIA1a-transfectants 
inhibited anchorage-dependent and anchorage-independent 
cell proliferations (Supplementary Figure S11). These 
results suggest that overexpressed cytoplasmic TIA1 
promotes ESCC tumorigenesis at least partly through its 
binding with SKP2 and CCNA2 mRNAs and induction of 
SKP2 and CCNA2 protein overexpression.
DISCUSSION
To our knowledge, this study is the first to 
demonstrate the clinical and functional significance of 
the TIA1 protein in ESCC tumorigenesis. Previously, a 
few reports described the expression of TIA1 in human 
carcinomas. The overexpression of TIA1 transcript has 
been reported in hepatocellular carcinoma tissues compared 
with paired adjacent non-tumor tissues using multiple 
samples [13]. In contrast, Izquierdo and his colleague 
showed the downregulation of the TIA1 protein in a subset 
of epithelial tumors, relative to normal tissues [14, 28]. 
Using a larger set of human ESCC cases, we demonstrated 
that TIA1 is overexpressed and ectopically localized to the 
cytoplasm, and that cytoplasmic TIA1 immunoreactivity 
is an independent prognosticator of overall survival. In 
addition, we demonstrated the oncogenic activity of TIA1, 
particularly TIA1a, and its molecular mechanisms, at least 
in part, using a series of experiments in ESCC cells. Our 
results suggest that TIA1 works as an ESCC oncogene and 
is likely to be a marker of malignant potential as well as a 
possible therapeutic target for this tumor type.
Most RBPs, including TIA1, Hu-antigen R (HuR) 
and AUF1, are expressed predominantly in the nucleus 
and shuttle between the nucleus and cytoplasm. Their 
cytoplasmic abundance is substantively linked to their 
effects on target mRNAs, and dysfunction in their 
subcellular distribution may have pathological consequences 
[29]. Indeed, cytoplasmic HuR expression has been shown 
to be associated with malignant clinicopathological 
features and poor prognosis in ESCC, indicating that 
ectopically localized HuR is involved in cancer-promoting 
RNA metabolism and contributes to the progression of 
ESCC [30]. In contrast, the cytoplasmic localization of 
TIA1 protein in epithelial tumor cells has not been well 
analyzed, although the nucleo-cytoplasmic shuttling of 
TIA1 under stress conditions has been described in some 
cells [31]. Because TIA1 overexpression and cytoplasmic 
localization are commonly observed in various squamous 
cell carcinomas, cancer-promoting effects of TIA1 through 
cytoplasmic localization might be cell lineage-specific.
Until now, each TIA1 isoform was considered to 
have equivalent RNA binding properties and subcellular 
distribution because these isoforms share most known 
motifs. Thus, most previous studies used the shorter 
TIA1b isoform to analyze TIA1 function by exogenously 
introducing recombinant constructs [11, 28]. In this study, 
we found that TIA1a and TIA1b exert distinct effects 
on ESCC cell proliferation: TIA1a promotes anchorage-
dependent and anchorage-independent cell proliferation, 
whereas TIA1b tends to inhibit cell proliferation and/or 
induces cell death. Therefore, the oncogenic activities of 
TIA1 we found are not inconsistent with previous reports 
demonstrating that TIA1 works as a tumor suppressor 
[12, 14, 28]. Because a larger fraction of TIA1a localizes 
to the cytoplasm, compared with TIA1b, and because 
exogenously introduced each isoform shows different 
mRNA binding affinities, TIA1a may function as an 
oncogene in ESCC through localizing to the cytoplasm 
and contributing to specific aspects of RNA metabolism. 
Although how transcription of those isoforms were 
regulated differentially in normal and tumor cells and 
how the 11 amino acid residues contribute to them remains 
unclear, the functional modification of the TIA1a isoform 
by focusing on the 11 amino acid residues is a potential 
therapeutic target for ESCC. This hypothesis is supported, 
in part, by recent reports showing that the expression 
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Table 3: Functional pathways of TIA1 target genes
KEGG Pathway Term P value (FDR)
hsa04110 Cell cycle 1.14E–04
hsa03040 Spliceosome 4.37E–04
hsa04722 Neurotrophin signaling pathway 0.006
hsa04114 Oocyte meiosis 0.031
Figure 5: Binding of TIA1 with mRNAs of putative target mRNAs and its effect on protein levels in ESCC cells. 
(A) Bindings between TIA1 and the nine putative target transcripts encoding cell cycle regulatory proteins identified through RIP-chip and 
RIP-seq (Supplementary Table S5) using anti-TIA1 antibody, as well as the known target, FAS mRNA, were validated by qPCR after RIP 
using KYSE180 cells. TIA1-mRNA bindings were measured by RIP followed by qPCR amplification and expressed as the enrichment of 
individual mRNAs in the TIA1 IP relative to an IgG IP. The data were normalized to the levels of GAPDH mRNA, an abundant mRNA that 
is not a target of TIA1 and that is present as a low-level co-precipitated contaminant in all IP samples. Representative results (mean ± SD, 
n = 3) of four independent experiments are shown. (B) Effects of TIA1 silencing on the expression of putative target mRNAs in ESCC cells. 
KYSE180 cells were transfected with 10 nM TIA1-specific or control siRNA for 48 h. The amounts of the 10 target mRNAs were measured 
by qPCR using GAPDH mRNA as an endogenous control. The values are expressed as fold changes (mean ± SD, n = 3) compared with the 
respective values in control siRNA-transfected cells. (C) Effects of TIA1 silencing on the expression of proteins encoded by the putative 
target genes in ESCC cells. KYSE140, KYSE180, TE4, or TE8 cells were transfected with 10 nM TIA1-specific or control (−) siRNA for 
48 h. The levels of SKP2, CCNA2, CHK1, CHK2 and TIA1 proteins were measured by western blot analysis using GAPDH as a loading 
control. (D) Effects of exogenous overexpression of each TIA1 isoform on the expression of proteins encoded by putative target genes in 
ESCC cells. Lysates were prepared from KYSE190 or KYSE2270 cells overexpressing TIA1. The levels of SKP2, CCNA2 and exogenous 
TIA1 proteins were measured by western blot analysis using GAPDH as a loading control.
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Figure 6: Differing effects of TIA1 on the SKP2 and CCNA2 genes in ESCC cells. (A) Biotinylated transcripts from the SKP2 
5′ UTR, the SKP2 ORF, the SKP2 3′ UTR, the CCNA2 5′ UTR, the CCNA2 ORF and the CCNA2 3′ UTR, as well as a biotinylated fragment 
of the GAPDH 3′ UTR (negative control), were prepared. Bindings between TIA1 and each fragment were tested by biotin pulldown assays 
using cell lysates extracted from KYSE180 cells. The amounts of TIA1 in pulldown samples were determined by western blot analysis 
using an anti-TIA1 antibody. Similar results were obtained in three independent experiments. (B) Effects of TIA1silencing on the stability 
of SKP2 and CCNA2 mRNA were determined in KYSE180 cells transfected with control siRNA or TIA1 siRNA. After treatment with 
2 µg/mL actinomycin D, the amounts of SKP2 (left), CCNA2 (middle) and GAPDH (right) mRNAs in cells were measured by qPCR and 
normalized to 18S rRNA levels. The data (mean ± SD, n = 3) are expressed as percentages of SKP2, CCNA2 or GAPDH mRNA levels 
before exposure to actinomycin D (time 0). *significantly different from the control value by Student’s t test (P < 0.05). (C) TIA1 increases 
the stability of SKP2 mRNA through its 3′ UTR. The pmirGLO-SKP2 plasmid expressing the chimeric reporter transcript bearing the Luc2 
CDS linked to the SKP2 3′ UTR or control plasmid (pmirGLO) was co-transfected with control siRNA or TIA1 siRNA into KYSE180 
cells for 48 h. After treatment with 2 µg/mL actinomycin D, the amounts of Luc2 mRNA was measured by qPCR and normalized to 18S 
rRNA levels. Data (mean ± SD, n = 3) are expressed as percentages of luciferase mRNA level before exposure to actinomycin D (time 0). 
*significantly different from the control value by Student’s t test (P < 0.05). (D) Relative polyribosome distribution of the CCNA2 mRNA 
(left) and the housekeeping GAPDH mRNA (right) in TIA1 knockdown cells and control KYSE180 cells was analyzed by sucrose gradient 
fractionation. From left to right, percentages of the total mRNA in fractions lacking ribosomes or ribosome subunits (fractions 1 and 2), 
fractions containing ribosome subunits or single ribosomes (fractions 3 to 7), and fractions spanning polysomes of increasing molecular 
weights (fractions 8 to 16) were shown (see Supplementary Figure S9C). Representative data are from three independent experiments. 
(E) IHC detection of TIA1, SKP2 and CCNA2 in primary ESCC tissues. Serial sections of ESCC were subjected to immunohistochemistry 
with goat anti-TIA1 (top), rabbit anti-SKP2 (middle) or mouse monoclonal anti-CCNA2 (lower) antibodies. Scale bars: 40 μm.
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pattern of each TIA1 isoform is defined by tissue type 
and that TIA1b has greater splicing stimulatory activity 
than TIA1a [11]. Isoform-specific subcellular localization 
and influences on the mRNA binding affinities of AUF1, 
which has four isoforms, have also been reported [32–35].
RBPs coordinate a set of multiple functionally related 
genes by orchestrating their splicing, export, stability, 
localization and translation in cellular processes [36]. In 
ESCC cells, over-representation of specific pathways in the 
TIA1-associated gene set revealed that TIA1 coordinates 
the expression of a gene cluster encoding cell cycle 
regulators. This in silico prediction corresponded with the 
results of our in vitro functional experiments and with the 
clinicopathological significance of TIA1 immunoreactivity 
in ESCC cases, supporting our hypothesis that TIA1 
is a possible therapeutic target for simultaneously and 
efficiently manipulating various target genes/pathways 
contributing to esophageal carcinogenesis.
Most of the specific cis elements that affect mRNA 
decay and/or translation of a subset of transcripts are found 
in the 5′ and 3′ UTRs, and the most well-known of these 
motifs are the adenine-uridine-rich element sequences 
(AREs) [37–39]. TIA1 was reported to be a negative 
posttranscriptional modulator through its bindings with 
AREs by stimulating assembly of the translational silencer 
complex that was routed to discrete cytoplasmic SGs [40]. 
Because some RBPs can act as both positive and negative 
posttranscriptional regulators [41–44], the finding that the 
expression levels of SKP2 and CCNA2 proteins increased 
through bindings between TIA1 protein and their transcripts 
was not surprising. Our results suggested that TIA1 binds to 
the 3′ UTR of SKP2 mRNA, resulting in the attenuation of 
mRNA decay, while TIA1 binds to the 5′ UTR and/or ORF 
of CCNA2 mRNA, resulting in the increased translation 
initiation without acquisition of mRNA. Because previous 
studies predicted the presence of TIA1 binding motifs 
in the 3′ UTR of SKP2 and 5′ UTR of CCNA2 mRNAs 
[18], TIA1 might be a suppressor of mRNA decay and 
translational inducer of SKP2 and CCNA2, respectively. 
Further elucidation of the precise mechanisms by which 
TIA1 increases/decreases the expression of a set of genes 
will reveal novel physiological and pathophysiological 
functions of TIA1.
MATERIALS AND METHODS
Cell lines and primary tissue samples 
In total, 45 ESCC cell lines were used, 34 of which 
belonged to the KYSE series established from surgically 
resected tumors [45] obtained from Dr. Yutaka Shimada 
or provided by the Japanese Collection of Research 
Bioresources (JCRB, Ibaraki, Japan). Ten were from the 
TE series provided by the Cell Bank, RIKEN BioResource 
Center (Tsukuba, Japan), and the T.T cell line was 
provided by JCRB. 
ESCC tumor samples were obtained from 143 patients 
with histologically proven primary ESCC who underwent 
esophagectomy (potentially curative R0 resection) at the 
Kyoto Prefectural University of Medicine Hospital (Kyoto, 
Japan) between 1998 and 2011. The samples were fixed 
with formalin for 24 h and then embedded in paraffin. 
Among the patients, 65 received preoperative neoadjuvant 
therapy with FP (Table 1, Supplementary Table S1), and 
39 received postoperative adjuvant chemotherapy with 
low-dose FP [5-fluorouracil (250–500 mg/body/day) plus 
cisplatin (10 mg/body/day)] and oral fluoropyrimidine 
[5-fluorouracil (150–200 mg/ body/day) or UFT (300–400 
mg/body/day)] for three years [46]. None had synchronous 
or metachronous multiple cancers in other organs. Relevant 
clinical and survival data were available for all patients. In 
this series, all M1 tumors had distant lymph node metastases 
but no organ metastasis. Disease stage was defined in 
accordance with the International Union Against Cancer 
tumor-lymph node-metastases (TNM) classification [47]. 
The median follow-up period for the surviving patients 
was 40.5 months (range, 0.16 to 156.9 months). Additional 
tissue samples, including normal and precancerous regions 
of the esophagus and non-esophageal SCC, were also 
obtained from patients treated at Tokushima University. 
Formal written consent was obtained from all patients after 
approval of all aspects of these studies by the local ethics 
committee (Kyoto Prefectural University of Medicine and 
Tokushima University).
Antibodies
The antibodies used in this study are listed in 
Supplementary Table S6.
Immunohistochemical staining and scoring
Paraffin-embedded sections (4-µm thick) were 
subjected to IHC staining for each protein using the 
avidin–biotin-peroxidase method. Briefly, antigen retrieval 
was performed by heating dewaxed and dehydrated 
sections in Dako Real Target Retrieval Solution (DAKO, 
Glostrup, Denmark) at 98°C for 30 min. Then, the sections 
were treated with 0.3% H2O2 for 30 min to quench the 
endogenous peroxidase and treated with protein blocker. 
Next, the sections were incubated with primary antibodies at 
4°C overnight. After incubation with secondary antibodies, 
an R.T.U. VECTASTAIN Universal Quick Kit (Vector 
Laboratories; Burlingame, CA, USA) and a Universal 
LSAB™+ Kit/HRP (DAKO) were used for colour 
development with diaminobenzidine tetrahydrochloride. The 
sections were counterstained with Mayer’s hematoxylin, 
dehydrated in ascending grades of ethanol and mounted.
Tumor tissues were compared with paired non-
tumor tissues. The percentage of the total cell population 
expressing the target protein and the overall staining 
intensity in tumor cells were evaluated for each case at 
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200× magnification. Expression of a target protein was 
considered positive when over 10% of the tumor cells 
showed strong or diffuse staining. The nuclear TIA1 
staining intensity was considered positive (+) when the cell 
showed staining that was stronger than that seen in non-
tumor esophageal epithelial cells in the parabasal layer, 
whereas the intensity of cytoplasmic TIA1 staining was 
considered positive (+) when the cells more or less showed 
staining. All stained slides were blindly and independently 
evaluated by two investigators without knowledge of the 
clinicopathological data, and any discordant result was 
settled by using a conference microscope.
Quantitative real-time PCR
One microgram of total RNA was reverse-
transcribed using the PrimeScript RT reagent kit (TaKaRa, 
Otsu, Japan). Transcript levels were quantified using the 
specific primer sets (Supplementary Table S7) and SYBR 
Green Master Mix (Applied Biosystems, Waltham, MA, 
USA), as described elsewhere [48]. GAPDH mRNA and 
18S rRNA levels were also measured and used as internal 
controls for normalization.
Western blot analysis
Whole-cell lysate preparation and western blot 
analysis were performed as previously described [49]. 
Subcellular components were isolated using a NE-PER 
Nuclear Protein Extraction Kit (Thermo Fisher Scientific, 
Waltham, MA, USA) according to the manufacturer’s 
instructions.
Fluorescent immunocytochemical staining 
Cells were cultured on chamber slides, fixed in 
4% paraformaldehyde for 30 min at room temperature, 
permeabilised with 0.1% Triton X-100 in phosphate-
buffered saline (PBS) for 1 min and treated with 
blocking reagent (1% BSA) for 30 min. After the cells 
were incubated with primary antibodies for 1 h at room 
temperature, the bound antibody was visualized using 
fluorescence-labelled secondary antibodies. After 
mounting using ProLong Gold Antifade Reagent with 
4′, 6-diamidino-2-phenylindole (DAPI), the cells were 
observed under a fluorescence microscope (LSM510; Carl 
Zeiss, Oberkochen, Germany).
Plasmid construction
The full coding sequences of human TIA1 variant 1 
(NM_022037), TIA1 variant 2 (NM_022173), SKP2 
(NM_005983), and CCNA2 (NM_001237) were amplified 
by PCR (Supplementary Table S7) using cDNA prepared 
from KYSE140 cells. These coding sequences were cloned 
into the mammalian expression vector pCMV-3Tag1A 
(Stratagene, La Jolla, CA, USA) to append the FLAG 
epitope to their NH2 termini. FLAG-tagged TIA1 variants 
were amplified by PCR (Supplementary Table S7) and 
cloned into the retroviral vector pMXs-Neo (Cell Biolabs, 
San Diego, CA, USA). The 3′ UTR of SKP2 were amplified 
by PCR (Supplementary Table S7) using cDNA prepared 
from KYSE140 cells, and ligated into the pmirGLO vector 
(Promega, Madison, WI, USA) to generate the plasmid 
expressing a chimeric RNA that contains the Luc2 CDS 
linked to the SKP2 3′ UTR (pmirGLO-SKP2).
Stable transfection experiments 
To establish ESCC cell lines stably overexpressing 
each TIA1 isoform, cells were infected with each TIA1 
variant-expressing retroviruses and selected by treatment 
with 0.5 mg/mL G418 for four weeks. Control cells were 
obtained using retroviruses obtained from the empty pMXs-
Neo vector that were packaged in PLAT-A cells. Clones 
were subsequently isolated, subcultured and tested for TIA1 
overexpression by western blot and FIC.
Transient transfection experiments
Various siRNAs targeting mRNAs of TIA1 (#1-3), 
each TIA1 isoform, SKP2, and CCNA2, as well as control 
siRNAs (Supplementary Table S8), were transfected 
separately into ESCC cells at a final concentration of 10 
nM using Lipofectamine RNAiMax reagent (Invitrogen, 
Carlsbad, CA, USA). A control plasmid (pCMV-3Tag1A), 
a pCMV-3Tag1A-containing FLAG-tagged TIA1 variant 1 
(pTIA1[v1]-FLAG), a pCMV-3Tag1A-containing FLAG-
tagged TIA1 variant 2 (pTIA1[v2]-FLAG), and pmirGLO-
containing SKP2 3′ UTR (pmirGLO-SKP2) were transfected 
separately into ESCC cell lines or HEK293 cells using 
Lipofectamine-2000 reagent (Invitrogen). 
Cell proliferation and cell cycle analyses
Cell growth was assessed at the indicated time after 
cell seeding (5 × 103 cells/96-well plate) using a water-
soluble tetrazolium (WST) salt assay (Cell Counting 
Kit-8; Dojindo, Mashikimachi, Japan) according to the 
manufacturer’s instructions. The results are expressed as 
the mean absolute absorbance at the indicated time divided 
by the mean absolute absorbance of each sample cultured 
for 24 h after seeding.
For colony formation assays, cells infected with 
either mock-, pTIA1[v1]-FLAG- or pTIA1[v2]-FLAG-
expressing retroviruses (1,000 cells/well) were plated in 
six-well plates and treated with 0.5 mg/mL G418 for two 
weeks. The colonies in each well were stained with crystal 
violet, and the areas of colonies formed were determined 
using ImageJ software (http://imagej.nih.gov/ij/).
For spheroid formation assays, 100 μL/well of cell 
suspensions at optimized densities (10,000 cells/mL) were 
dispensed into PrimeSurface 96-well round-bottomed 
plates (Sumitomo Bakelite, Tokyo, Japan). Plates were 
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centrifuged for 5 min at 1,000 rpm and incubated at 37°C 
in an atmosphere of 5% CO2. The areas of the spheroids 
formed were determined using ImageJ software.
Cell cycles were evaluated by FACS as described 
elsewhere [50]. Cell counting was performed using a 
FACSVerse flow cytometer (Becton Dickinson, Mountain 
View, CA, USA). 
Ribonucleoprotein immunoprecipitation assay 
Immunoprecipitation of ribonucleoprotein complexes 
was performed using the RiboCluster Profiler RIP-
Assay kit (Medical & Biological Laboratories, Nagoya, 
Japan) according to the manufacturer’s protocol. Briefly, 
cytoplasmic lysates (500 μg protein) prepared from ESCC 
cells were incubated for 1 h at 4°C with 80 µL of a 50% 
(v/v) suspension of protein A agarose beads precoated with 
15 µg of rabbit IgG1 (Medical & Biological Laboratories) 
or rabbit anti-TIA1 antibody (Supplementary Table S6). 
After the quality and quantity of RNAs in the input lysates 
and the IP materials were assessed using an Agilent 2100 
Bioanalyzer (Agilent Technologies, Santa Clara, CA, 
USA), total transcripts and immunoprecipitated transcripts 
were analyzed using microarray and/or RNA sequencing 
(RNA-seq). 
Microarray data were obtained using a whole human 
genome microarray (8 × 60 k, Agilent Technologies), as 
described previously [50], and analyzed using GeneSpring 
13.0 software (Agilent Technologies). All microarray data 
are available at the Gene Expression Omnibus (GSE71342).
To prepare the template for RNA-Seq, first- and 
second-strand cDNA synthesis was performed using 100 ng 
of RNA. This was followed by single-primer isothermal 
amplification using an NEBNext Ultra RNA Library Prep 
Kit for Illumina (New England Biolabs, Ipswich, MA, 
USA) according to the manufacturer’s protocol. These steps 
amplified polyA- and non-polyA-tailed RNAs and removed 
ribosomal RNA. The cDNA library was sequenced using 
an Illumina MiSeq instrument (Illumina). The quality of 
the bases was checked using the FASTQC program. Called 
bases were aligned to the human hg19 genome using the 
Tophat program, the Bowtie algorithm and Ensembl hg19 
(v62) as gene model annotations, followed by genomic 
mapping. The aligned reads were assembled into transcripts 
(both known and novel) using the Cufflinks program 
with Ensembl hg19 (v62) transcripts as a guide. FPKM 
(fragments per kilobase of exon model per million mapped 
reads) values were calculated after fragment bias correction 
and normalization to total hits. The data were visualized in 
the UCSC genome browser. All RNA-seq data are available 
at the DNA Data Bank of Japan (PRJDB4086).
After mRNA expression was normalized to 
constitutive mRNA expression levels determined by 
microarray, the association of mRNAs with TIA1 was 
assessed by estimating the enrichment of mRNAs in TIA1 
IP samples, compared with those of GAPDH mRNA, an 
abundant mRNA that is not a target of TIA1.
The enrichment analyses of the set of TIA1 target 
genes and functional pathways related to this gene set 
were performed using GO enrichment analysis and KEGG 
pathway analysis, respectively. Over-representation 
of specific GO and KEGG pathways in a gene set was 
statistically analyzed by DAVID Bioinformatics Resources 
6.7 software (http://david.abcc.ncifcrf.gov/home.jsp) 
[51, 52]. The enrichment P-value calculation, i.e. number 
of genes in the list that hit a given biology class as compared 
to pure random chance, was performed with Benjamini and 
Hochberg multiple testing correction.
Biotin pulldown analysis 
cDNA corresponding to each gene fragment 
was used as a template for the in vitro synthesis of 
biotinylated transcripts. The T7 RNA polymerase 
promoter sequence was added to the 5′ ends of all of 
the fragments using PCR (Supplementary Table S7). The 
biotinylated GAPDH 3′ UTR was prepared as previously 
described [49]. Biotinylated RNAs were synthesized 
using the MaxiScript T7 kit (Ambion, Austin, TX, 
USA). Whole-cell lysates (40 µg for each sample) were 
incubated with one of the purified biotinylated fragments 
(4 µg) for 1 h at room temperature. Complexes were 
isolated with paramagnetic streptavidin-conjugated 
beads (Dynabeads M280 Streptavidin; Invitrogen), and 
bound proteins in the pulldown materials were assayed 
by western blot analysis using anti-TIA1 antibody as 
described above.
mRNA decay assay
To measure relative mRNA stabilities in cells with 
normal TIA1 or reduced TIA1 levels, cultures were treated 
with 2 μg/mL transcriptional inhibitor, actinomycin D 
(Merck Millipore, Darmstadt, Germany), for the indicated 
times. At subsequent times, mRNA levels were measured 
by qPCR and normalized to 18S rRNA levels. The data 
are expressed as percentages of each mRNA level before 
exposure to actinomycin D (time zero). 
Protein decay assay
To measure relative protein stabilities in cells with 
normal TIA1 or reduced TIA1 levels, cultures were treated 
with 0.1 mg/mL translational inhibitor, cycloheximide 
(Sigma-Aldrich, St Louis, MO, USA), for the indicated 
times. At subsequent times, protein levels were assayed by 
western blot analysis.
Sucrose gradient polyribosome fractionation
KYSE180 cells at < 80% confluence were incubated 
for 5 min in 0.1 mg/mL cycloheximide and then lifted 
in 1mL PEB lysis buffer (0.3 M NaCl, 15 mM MgCl2, 
15 mM Tris-HCl, pH 7.6, 1% Triton X-100, and 0.1 mg/mL 
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cycloheximide) by scraping and lysed on ice for 10 min. 
The lysates were centrifuged at 14,000 rpm at 4°C for 
10 min. The supernatant (1 mg protein) was layered onto 
liner 10–50% sucrose gradient. After centrifuging at 4°C 
for 90 min at 39,000 rpm, 500 μL fractions were collected. 
RNA for qPCR in each fraction was extracted with TRIzol-
LS Reagent (Thermo Fisher Scientific) according to the 
manufacturer’s instructions.
Luciferase reporter assay 
PmirGLO-SKP2 or control plasmid (pmirGLO) was 
transfected into ESCC cells in which endogenous TIA1 was 
silenced by siRNA. After 48 h, cultures were treated with 
2 μg/mL actinomycin D (Merck Millipore) for the indicated 
times. At subsequent times, Luc2 mRNA levels were 
measured by qPCR and normalized to 18S rRNA levels. 
The data are expressed as percentages of each mRNA level 
before exposure to actinomycin D (time zero).
Statistical analysis
The clinicopathological variables pertaining to the 
corresponding patients were analyzed by using the χ2 test 
or Fisher’s exact test. For survival analysis, Kaplan–
Meier survival curves were constructed for groups based 
on univariate predictors, and differences between the 
groups were tested using the log-rank test. Univariate 
and multivariate survival analyses were performed using 
the likelihood ratio test of the stratified Cox proportional 
hazards model. Differences between subgroups were 
evaluated using Student’s t-test. Differences were assessed 
with a two-sided test and considered significant at the P < 
0.05 level.
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